npj Breast Cancer

Article	Citations
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer	748
Biological correlates associated with high-risk breast cancer patients identified using a computational method	344
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer	205
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination	144
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers	142
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab	124
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021	110
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer	105
International survey on invasive lobular breast cancer identifies priority research questions	99
CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer	97
A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence	93
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer	82
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer	75
Risk factors for second primary cancer in patients who survive breast cancer	73
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer	72
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer	71
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors	71
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines	65
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer	61
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)	59
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events	54
Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study	53
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial	52
Survival outcomes after omission of surgery for ductal carcinoma in situ	51
Breastfeeding attributable fraction of triple negative breast cancer in the US	51

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays	50
Neighborhood deprivation and oncotype DX recurrence scores among Black and White women: the interplay between race, place, and tumor biology	47
Host-derived interleukin-1α drives tumor immunosuppression by reprogramming tumor-associated myeloid cells	45
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions	44
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice	43
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)	43
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer	43
Temporal evolution of breast cancer brain metastases treatments and outcomes	43
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer	42
Circulating tumor DNA validity and potential uses in metastatic breast cancer	41
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer	41
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center	39
Kataegis in clinical and molecular subgroups of primary breast cancer	39
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling	38
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification	38
Understanding metastasis mixed-treatment responses through genomic analyses	36
AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer	36
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer	35
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 2016	34
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment	34
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models	33
Breast cancers arising in high mammographic density tissue harbor tumor-promoting immune profiles	33
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries	32
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance	32
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin	32
Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States	32
Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer	31
Functional assays for BRCA1 and BRCA2 variant analysis: new tools and their applications	31
Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer	30
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer	30
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial	29
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies	28
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program	28
Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6	28
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment	27
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer	27
USP7 inhibition perturbs proteostasis and tumorigenesis in triple-negative breast cancer	26
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer	26
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study	26
Large language model (ChatGPT) as a support tool for breast tumor board	26
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry	25
Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancer	24
A systematic review of determinants of breast cancer risk among women with benign breast disease	24
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab	24
Cook and Move for Your Life, an eHealth intervention for women with breast cancer	24
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models	23
Prognostic value of structural variants in early breast cancer patients	23
SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning	23
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies	23
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy	23

Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer	23
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort	22
Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history	22
Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation	22
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer	22
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers	21
Beyond timing, toward precision: insights from CDK4/6 inhibitor trials in metastatic breast cancer	21
Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling	21
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer	21
Author Correction: Advancing equitable access to innovation in breast cancer	21
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer	21
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation	21
Prognostic consistency of oncotype DX® molecular assay across racial groups in early-stage hormone receptor-positive breast cancer	20
Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes	20
Evaluating mammographic density′s contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors	20
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence	20
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy	19
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape	19
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer	19
Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer	19
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer	19
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry	19
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women	19
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention	18
Plasma C-peptide mammographic features and risk of breast cancer	18
Proteogenomic characterization of invasive breast tumors in young women	18
The association between local therapies and survival among patients with metastatic inflammatory breast cancer	18
Racial discrimination among women seeking breast cancer care	18
Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer	17
Author Correction: Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer	17
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases	17
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer	17
Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer	17
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer	17
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41	16
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study	16
Diagnostic Performance of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Evaluating Neoadjuvant Therapy Pathological Response in Breast Cancer	16
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer	16
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer	16
Impact of neoadjuvant chemotherapy on local breast microbiota and macrophages in ER-positive breast cancer with links to treatment response	16
Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer	16
Post-diagnosis weight trajectories and mortality among women with breast cancer	16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence	16
Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer	16
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer	15
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events	15
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer	15
Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour	15
Artificial intelligence in breast pathology – dawn of a new era	14
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts	14
Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer	14
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib	14
Advancing equitable access to innovation in breast cancer	14
Genomic landscape of breast cancer in elderly patients	14
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer	14
Disparities in breast cancer incidence and survival by age, race, and molecular subtype in US women	14
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer	13
Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer	13
The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status	13
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study	13
Estrogen receptor β target gene expression reveals novel repressive functions in aggressive breast cancer	13
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial	13
Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors	13
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics	13
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study	12
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy	12
Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer	12
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer	12
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer	12
Artificial intelligence assisted multi-model pathological diagnosis of breast cancer based on multispectral autofluorescence images	12
MammOnc-DB, an integrative breast cancer data analysis platform for target discovery	12
PCSK9 rs562556 variant and survival in BRCA1 mutation carriers and mutation-negative familial breast cancer	12
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer	12
Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance	12
Genomic landscapes of breast cancer in African populations: a systematic review	12
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients	11
External validation of four breast cancer risk prediction models for personalized screening in a prospective Dutch screening cohort	11
Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer	11
Development and internal validation of mammography feature-based prognostic models for distant recurrence-free survival of invasive breast cancer in a screening cohort	11
An emerging generation of endocrine therapies in breast cancer: a clinical perspective	11

The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer	11
Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE	11
Bridging the gap: ctDNA, genomics, and equity in breast cancer care	11
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease	10
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer	10
Computerized cognitive training improves cognitive function in primary breast cancer survivors	10
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients	10
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer	10
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden	10
Trimester of diagnosis affects tumor characteristics and survival in breast cancer during pregnancy: first results from the STURGATE collaboration	10
Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation	10
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications	10
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools	10
Facing death: the last drawings of a woman with breast cancer at the end of life	10
Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer	10
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management	10
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer	10
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function	10
WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design	10
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study	9
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ	9
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning	9
Validation of pathology-based triage for the 21-gene recurrence score: a meta-analysis and qualitative synthesis of the Magee equations	9
Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs	9
Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision	9
Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes	9
Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers	9
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer	8
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer	8
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy	8
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer	8
Author Correction: Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis	8
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer	8
ACSS2-mediated metabolic-epigenetic crosstalk drives Fulvestrant resistance and represents a novel therapeutic target	8
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade	8
Effects of acute exercise on inflammatory and metabolic biomarkers in women: a randomized controlled trial	8
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes	8
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers	8
The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer	8
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis	8
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer	8
Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer	8
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes	8
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial	8
HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis	7
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death	7
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab	7
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment	7
Author Correction: Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer	7
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis	7
Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer	7
Women’s preferences for breast cancer risk-reducing medications: a discrete choice experiment study	7
Allostatic load as a predictor of postoperative complications in patients with breast cancer	7
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer	7
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer	7
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer	7
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial	7
Programmable local immunochemotherapy for triple-negative breast cancer via spatiotemporally controlled release of CpG oligodeoxynucleotides, gemcitabine, and paclitaxel	6
Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis	6
Modeling tumor relapse using proliferation tracing and ablation transgenic mouse	6
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients	6
Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology	6
Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer	6
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)	6
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling	6
Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer	6
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy	6
Machine learning-based identification of high-risk triple-negative breast cancer patients despite pathological complete response after neoadjuvant chemotherapy	6
Immunotherapy in breast cancer: an overview of current strategies and perspectives	6
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer	6
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer	6
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study	6
Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subset	6
Multimodal imaging and artificial intelligence for response assessment to neoadjuvant therapy in breast cancer: a comprehensive review	6
Author Correction: Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing	6
CBD-oil as a potential solution in case of severe tamoxifen-related side effects	6
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis	6
Predicting pathologic ≥N2 disease in women with breast cancer	6
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies	6
Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer	6
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer	6
Cancer cell-monocyte co-culture spheroids recapitulate pro-tumorigenic, immunosuppressive, and drug-resistant microenvironments in brain metastatic breast cancer	6
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC	5
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy	5
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey	5
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer	5
Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives	5
Characterization of body composition dynamics throughout treatment in patients with early-stage breast cancer	5
Tractable mouse TNBC models capture the heterogeneous tumor immune microenvironment and adaptation to PD-L1 blockade	5
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ	5
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets	5
Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP)	5
No evidence for genotype-treatment interactions with breast cancer endocrine therapy adverse effects in UK Biobank	5
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502	5
Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer	5